Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA4 | P48058 | 14/20 | 0.60 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.40 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.40 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7031129 | 1.00 | GRIA4 (0.60) | GRIA4GRIA1GRIA2GRIA3IDO1 | |
| SCHEMBL6554399 | 1.00 | GRIA4 (0.60) | GRIA4GRIA1GRIA2GRIA3IDO1 | |
| SCHEMBL6565123 | 0.92 | GRIA4 (0.68) | GRIA4GRIA1GRIA2GRIA3 | |
| SCHEMBL5992695 | 0.87 | GRIA4 (0.71) | GRIA4GRIA1GRIA2GRIA3 | |
| SCHEMBL6847064 | 0.84 | GRIA4 (0.60) | GRIA4GRIA1GRIA2GRIA3SIGMAR1 | |
| SCHEMBL6936169 | 0.84 | GRIA4 (0.60) | GRIA4GRIA1GRIA2GRIA3 | |
| SCHEMBL6554706 | 0.84 | GRIA4 (0.60) | GRIA4GRIA1GRIA2GRIA3 | |
| SCHEMBL6847257 | 0.84 | GRIA4 (0.60) | GRIA4GRIA1GRIA2GRIA3SIGMAR1 | |
| SCHEMBL6554686 | 0.84 | GRIA4 (0.60) | GRIA4GRIA1GRIA2GRIA3 | |
| SCHEMBL338200 | 0.84 | GRIA4 (0.60) | GRIA4GRIA1GRIA2GRIA3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1390072-A2 | USE OF AN AMPA RECEPTOR POTENTIATOR FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF TYPE 2 DIABETES | ELI LILLY AND COMPANY (US) | 2004-02-25 | — | — | EP | disclosed |
| US-20030225127-A1 | Heterocyclic sulfonamide derivatives | BENDER DAVID MICHAEL (US) | 2003-12-04 | — | — | US | disclosed |
| EP-1309577-A2 | HETEROCYCLIC SULFONAMIDE DERIVATIVES AND THEIR USE FOR POTENTIATING GLUTAMATE RECEPTOR FUNCTION | ELI LILLY AND COMPANY (US) | 2003-05-14 | — | — | EP | disclosed |
| WO-2002089848-A2 | USE OF AN AMPA RECEPTOR POTENTIATOR FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF TYPE 2 DIABETES | ELI LILLY AND COMPANY (US) | 2002-11-14 | — | — | WO | disclosed |
| WO-2002014294-A2 | HETEROCYCLIC SULFONAMIDE DERIVATIVES AND THEIR USE FOR POTENTIATING GLUTAMATE RECEPTOR FUNCTION | ELI LILLY AND COMPANY (US) | 2002-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225127-A1 | Heterocyclic sulfonamide derivatives | GRIN2A, GRIN2B, GRIN1 | GRIA4 12/4885GRIA1 5/4885GRIA2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.